BUFFALO, N.Y., July 15, 2026 — MimiVax Inc., a clinical-stage biotechnology company dedicated to the development of innovative cancer immunotherapies, today announced that data cutoff has been reached for the SURVIVE trial…
Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication BUFFALO, N.Y., May 5, 2026 — Biotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center today jointly announced the launch of…
Buffalo, NY., February 12, 2025 Highlights: Ongoing clinical trial of SurVaxM in glioblastoma [SURVIVE] has successfully progressed following an interim analysis of trial data The clinical trial is designed to evaluate the safety,…
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma
Investors feature leading brain tumor venture philanthropy funds including the Brain Tumor Investment Fund (BTIF) and the Sontag Innovation Fund, along with MEDA Angels, Varia Ventures and private investors. Investment…
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
Buffalo, NY. December 15, 2022 - MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma (nGBM) in…
SurVaxM appeared to be safe and well-tolerated in pts with nGBM. SurVaxM was effective at stimulating survivin-specific immune responses and the primary endpoint was met.
First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is the first center to treat patients…